Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
2348.HK
Strong BuyDawnrays Pharmaceutical (Holdings) Limited · Healthcare · Hong Kong · $192M · Avg Vol: $12K/d
99
StockRankGet insider-trade alerts
Q
64
V
94
M
65
P/E (TTM)
6.3x
ROE
6.3%
D/E
0.0x
Dividend %
6.3%
COMPANY DESCRIPTION
Dawnrays Pharmaceutical (Holdings) Limited, an investment holding company, develops, manufactures, and sells non-patented pharmaceutical medicines in Mainland China and internationally. It operates in two segments, Intermediates and Bulk Medicines, and Finished Drugs.
FINANCIAL SUMMARY (HKD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 1.5B | 1.3B | 1.2B | 1.4B | -1.2% | 1.4B |
| EPS (HKD) | 0.28 | 0.25 | 0.44 | 0.16 | -16.3% | 0.16 |
| Shares | 1.5B | 1.5B | 1.5B | 1.5B | +0.3% | 1.5B |
| Debt | 9.8M | 140.6M | 40.5M | 90.4M | 109.6% | 90.4M |
| Equity | 3.1B | 3.3B | 3.9B | 3.9B | 8.6% | — |
| Op CF | — | — | — | — | — | — |
| Inv CF | -204.1M | -452.1M | 239.3M | -430.2M | — | — |
| Fin CF | -108.1M | 2.4M | -221.0M | -64.1M | — | — |
Loading 1Y...
PRICE (1Y)+0.0%
SMA 50SMA 200
Close
$0.1276
RSI (14)
53.8
52W High
$0.1578
From 52W High
0.8%
SCORE BREAKDOWN
Quality
64
ROIC
7.1%64.5
ROE
6.3%60.8
GP/Assets
13.9%34.1
Op. Margin
19.9%82.0
FCF/Assets
3.6%62.5
Piotroski
577.2
Int. Cover
50.0x89.3
D/E Ratio
0.02x78.4
Current Ratio
4.64x68.5
Value
94
P/E (TTM)
6.3x95.6
EV/EBITDA
-0.6x99.3
P/FCF
9.0x84.7
P/B
0.3x98.9
P/S
1.0x82.6
Div Yield
6.3%95.0
Momentum
65
52W High %
81%67.1
RS 6M
-7%56.5
SMA 50/200
0.93x41.8
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+175%85.3
Q Growth
52%74.2
FUNDAMENTALS
Market Cap
$192M
P/E (Forward)
2.3x
Gross Margin
45.3%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 2348.HK are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 2348.HK | Dawnrays Pharmaceutical (Holdings) Limited(you) | $192M | 99 | Strong Buy |
| 8049.HK | Jilin Province Huinan Changlong Bio-pharmacy Company Limited | $168M | 100 | Strong Buy |
| 3839.HK | CPBIO Holding Company Limited | $270M | 96 | Strong Buy |
| 2161.HK | JBM (Healthcare) Limited | $192M | 89 | Strong Buy |
| 2633.HK | Jacobson Pharma Corporation Limited | $267M | 94 | Strong Buy |
| 3613.HK | Beijing Tong Ren Tang Chinese Medicine Company Limited | $694M | 93 | Strong Buy |
| 0950.HK | Lee's Pharmaceutical Holdings Limited | $101M | 76 | Buy |
| 2005.HK | SSY Group Limited | $994M | 82 | Strong Buy |
| 0570.HK | China Traditional Chinese Medicine Holdings Co. Limited | $893M | 69 | Buy |
| 3320.HK | China Resources Pharmaceutical Group Limited | $3.7B | 93 | Strong Buy |
Peer medians: ROE 6.9% · P/E 11.5x · Gross margin 38.1%